Knoll Capital Management’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3M | Hold |
485,515
| – | – | 1.4% | 22 |
|
|
2026
Q1 | $2.18M | Buy |
485,515
+249,562
| +106% | +$1.25M | 1.21% | 21 |
|
|
2025
Q4 | $1.24M | Buy |
235,953
+173,264
| +276% | +$872K | 0.57% | 27 |
|
|
2025
Q3 | $331K | Hold |
62,689
| – | – | 0.18% | 36 |
|
|
2025
Q2 | $356K | Buy |
+62,689
| New | +$357K | 0.25% | 34 |
|
|
2022
Q4 | – | Sell |
-88,629
| Closed | -$269K | – | 22 |
|
|
2022
Q3 | $269K | Sell |
88,629
-1
| -0% | -$4 | 0.16% | 28 |
|
|
2022
Q2 | $461K | Hold |
88,630
| – | – | 0.26% | 31 |
|
|
2022
Q1 | $709K | Hold |
88,630
| – | – | 0.45% | 23 |
|
|
2021
Q4 | $651K | Sell |
88,630
-25,761
| -23% | -$473K | 0.36% | 22 |
|
|
2021
Q3 | $3.2M | Hold |
114,391
| – | – | 1.6% | 9 |
|
|
2021
Q2 | $4.46M | Hold |
114,391
| – | – | 2.33% | 9 |
|
|
2021
Q1 | $5.38M | Hold |
114,391
| – | – | 3.5% | 8 |
|
|
2020
Q4 | $4.49M | Hold |
114,391
| – | – | 3.06% | 6 |
|
|
2020
Q3 | $2.92M | Hold |
114,391
| – | – | 2.39% | 7 |
|
|
2020
Q2 | $8.15M | Hold |
114,391
| – | – | 4.71% | 4 |
|
|
2020
Q1 | $6.01M | Hold |
114,391
| – | – | 5.64% | 4 |
|
|
2019
Q4 | $9.35M | Buy |
114,391
+20,000
| +21% | +$1.41M | 6.9% | 4 |
|
|
2019
Q3 | $5.33M | Hold |
94,391
| – | – | 4.88% | 4 |
|
|
2019
Q2 | $11.3M | Hold |
94,391
| – | – | 9.23% | 3 |
|
|
2019
Q1 | $17.4M | Hold |
94,391
| – | – | 13.2% | 3 |
|
|
2018
Q4 | $16.8M | Hold |
94,391
| – | – | 19.17% | 3 |
|
|
2018
Q3 | $29.6M | Hold |
94,391
| – | – | 25.05% | 2 |
|
|
2018
Q2 | $37.8M | Hold |
94,391
| – | – | 32.09% | 1 |
|
|
2018
Q1 | $33.9M | Hold |
94,391
| – | – | 34.77% | 1 |
|
|
2017
Q4 | $37.4M | Hold |
94,391
| – | – | 32.97% | 1 |
|
|
2017
Q3 | $40.2M | Hold |
94,391
| – | – | 34.4% | 1 |
|
|
2017
Q2 | $15.1M | Hold |
94,391
| – | – | 20.02% | 3 |
|
|
2017
Q1 | $11.7M | Hold |
94,391
| – | – | 17.7% | 2 |
|
|
2016
Q4 | $11.4M | Buy |
94,391
+40,000
| +74% | +$6.26M | 20.08% | 2 |
|
|
2016
Q3 | $8.04M | Hold |
54,391
| – | – | 14.09% | 2 |
|
|
2016
Q2 | $3.21M | Hold |
54,391
| – | – | 1.04% | 7 |
|
|
2016
Q1 | $3.48M | Hold |
54,391
| – | – | 1.41% | 6 |
|
|
2015
Q4 | $4.57M | Hold |
54,391
| – | – | 1.69% | 6 |
|
|
2015
Q3 | $5.51M | Hold |
54,391
| – | – | 2.34% | 5 |
|
|
2015
Q2 | $6.88M | Buy |
54,391
+45,867
| +538% | +$6.89M | 2.22% | 5 |
|
|
2015
Q1 | $669K | Buy |
+8,524
| New | +$686K | 0.19% | 12 |
|
Other funds holding ABEO
ACM
AIC
Knoll Capital Management's ABEO Position: Q2 2026 in Review
Knoll Capital Management held its Abeona Therapeutics (ABEO) position steady in Q2 2026 at 485,515 shares worth $3M. The position accounts for 1.4% of the portfolio, ranked #22.
Knoll Capital Management first reported a position in ABEO in Q1 2015 and has held it in 36 quarters since. The position peaked at $40.2M in Q3 2017. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- Knoll Capital Management held 485,515 shares of Abeona Therapeutics worth $3M as of Q2 2026.
- Knoll Capital Management left its Abeona Therapeutics share count unchanged in Q2 2026.
- Abeona Therapeutics made up 1.4% of Knoll Capital Management's portfolio in Q2 2026, its #22 holding.
- Knoll Capital Management first reported a position in Abeona Therapeutics in Q1 2015 and has held it in 36 quarters since.
- Knoll Capital Management's Abeona Therapeutics position peaked at $40.2M in Q3 2017.
- 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.